Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries Post published:September 7, 2022 Post category:Press Release
Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global Post published:September 7, 2022 Post category:Press Release
BetterLife and Collaborators to Submit Key Joint Research Publication Post published:September 7, 2022 Post category:Press Release
MindMed to Participate in H.C. Wainwright Global Investment Conference USA – English USA – English USA – English Post published:September 7, 2022 Post category:Press Release
PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARXâ„¢ Ketamine Patch Post published:September 7, 2022 Post category:Press Release
PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022 Post published:September 7, 2022 Post category:Press Release
Psychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alcohol Use Disorder; Former MindMed CMO Alleges IP Was Syphoned off to Competitor; ARK Discusses Psychedelics Post published:September 6, 2022 Post category:Psychedelic Bulletin
Psychedelic Research Bulletin: July and August 2022 Post published:September 5, 2022 Post category:Psychedelics Research Review
Wesana Announces Sale of Clinic Management Services Organization Post published:September 3, 2022 Post category:Press Release
Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough Post published:September 2, 2022 Post category:Press Release